{"id":"cabergoline-pill","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Orthostatic hypotension"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL1201087","moleculeType":"Small molecule","molecularWeight":"451.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabergoline binds to dopamine D2 receptors on lactotroph cells in the anterior pituitary, mimicking dopamine's inhibitory effect on prolactin release. By reducing circulating prolactin levels, it restores normal gonadal function and fertility in patients with hyperprolactinemia. This mechanism makes it particularly useful in treating prolactin-secreting pituitary adenomas and restoring ovulatory cycles in women with elevated prolactin.","oneSentence":"Cabergoline is a dopamine D2 receptor agonist that suppresses prolactin secretion from the pituitary gland.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:49.974Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas)"},{"name":"Restoration of ovulatory cycles and fertility in women with hyperprolactinemia-induced anovulation"}]},"trialDetails":[{"nctId":"NCT07463235","phase":"PHASE3","title":"Safety and Potency of a High Cabergoline Dosage in Microprolactinomas","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-04","conditions":"Prolactinoma, Prolactin Excess","enrollment":70},{"nctId":"NCT06029673","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Early Second-Trimester Abortion or Pregnancy Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2024-02-07","conditions":"Lactation Suppressed","enrollment":69},{"nctId":"NCT04701333","phase":"PHASE2","title":"Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Loss","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-04-01","conditions":"Lactation Suppressed","enrollment":73},{"nctId":"NCT04096027","phase":"PHASE4","title":"Cabergoline Before or After Oocyte Collection for Follicular Resolution","status":"COMPLETED","sponsor":"Fertility Center of Las Vegas","startDate":"2019-09-23","conditions":"Infertility, Female","enrollment":70},{"nctId":"NCT00033111","phase":"PHASE2","title":"A Study of Cabergoline for the Treatment of Cocaine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-06","conditions":"Cocaine-Related Disorders, Substance-Related Disorders","enrollment":140},{"nctId":"NCT01395602","phase":"PHASE1, PHASE2","title":"Effect of Cabergoline on Weight and Glucose Tolerance","status":"COMPLETED","sponsor":"Columbia University","startDate":"2002-04","conditions":"Body Weight, Impaired Glucose Tolerance in Obese","enrollment":40},{"nctId":"NCT01651364","phase":"PHASE1","title":"A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2011-07","conditions":"Cocaine Dependence, Cocaine Abuse, Cocaine Addiction","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cabergoline Pill","genericName":"Cabergoline Pill","companyName":"Fertility Center of Las Vegas","companyId":"fertility-center-of-las-vegas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabergoline is a dopamine D2 receptor agonist that suppresses prolactin secretion from the pituitary gland. Used for Hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas), Restoration of ovulatory cycles and fertility in women with hyperprolactinemia-induced anovulation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}